{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T13:08:12Z","timestamp":1793624892108,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Backgrounds<\/jats:title>\n                    <jats:p>The aberrant activation of complement system is critically involved in lupus nephropathy. Recent study showed complement C3 inhibitor was effective in the treatment of lupus nephropathy. In this study, we investigate the effect of a novel complement C3 inhibitor, CRIg\/FH, in the treatment of lupus nephropathy in MRL\/lpr lupus mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We treated MRL\/lpr female mice with a dose escalation of CRIg\/FH (10, 5 and 2\u2009mg\/kg) by intraperitoneal injection twice weekly since 12\u2009weeks age. In addition, MRL\/lpr mice treated with intraperitoneal injection of normal saline or oral prednisone, along with C57BL\/6\u2009J healthy mice were maintained to serve as controls. We started 8-h urine collection weekly to screen proteinuria by measuring the levels of urine urea\/creatinine. Serum samples was collected at week 16 and 20 to measure levels of urea nitrogen, creatinine, and immunological markers (C3, C4, A-ds-DNA) before the mice were sacrificed at 20\u2009weeks age to collect kidneys for histopathological examinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overt skin lesions were observed in MRL\/lpr mice treated with normal saline, while skin lesion was not observed in CRIg\/FH treated MRL\/lpr mice. There was no overt proteinuria observed in MRL\/lpr mice treated with CRIg\/FH. Serum creatinine and BUN levels in MRL\/lpr mice was maintained in highest CRIg\/FH dose (10\u2009mg\/kg twice a week) to be significantly lower than that in prednisone treated MRL\/lpr mice at 20\u2009weeks age. In addition, CRIg\/FH treatment in MRL\/lpr mice results in a significantly elevated serum C3 and C4 levels when compared to prednisone treatment at both 16 and 20\u2009weeks. Furthermore, our study identified that serum level of A-ds-DNA was also significantly lower in CRIg\/FH treatment than that in predisone treated MRL\/lpr mice. Renal pathology confirmed that kidneys from CRIg\/FH treated MRL\/lpr mice suffered less from nephritis and complement disposition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results showed that the complement inhibitor CRIg\/FH can protect MRL\/lpr mice from lupus nephropathy by preserving renal function and glomerulus complement activation. Our findings support the positive effect of complement inhibitors in the treatment of lupus nephropathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-019-1599-0","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T09:03:34Z","timestamp":1574327014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The new complement inhibitor CRIg\/FH ameliorates lupus nephritis in lupus-prone MRL\/lpr mice"],"prefix":"10.1186","volume":"20","author":[{"given":"Yu","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guomin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7617-0872","authenticated-orcid":false,"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"issue":"4","key":"1599_CR1","doi-asserted-by":"publisher","first-page":"7917","DOI":"10.3390\/ijms16047917","volume":"16","author":"DY Yap","year":"2015","unstructured":"Yap DY, Lai KN. Pathogenesis of renal disease in systemic lupus erythematosus--the role of autoantibodies and lymphocytes subset abnormalities. Int J Mol Sci. 2015;16(4):7917\u201331.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1599_CR2","doi-asserted-by":"publisher","first-page":"J276","DOI":"10.1016\/j.jaut.2009.11.014","volume":"34","author":"M Chen","year":"2010","unstructured":"Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010;34(3):J276\u201386.","journal-title":"J Autoimmun"},{"issue":"5","key":"1599_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/BOR.0000000000000317","volume":"28","author":"J Couture","year":"2016","unstructured":"Couture J, Silverman ED. Update on the pathogenesis and treatment of childhood-onset systemic lupus erythematosus. Curr Opin Rheumatol. 2016;28(5):488\u201396.","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"1599_CR4","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ni0901-764","volume":"2","author":"PE Lipsky","year":"2001","unstructured":"Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol. 2001;2(9):764\u20136.","journal-title":"Nat Immunol"},{"issue":"7","key":"1599_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/jcp.56.7.481","volume":"56","author":"CC Mok","year":"2003","unstructured":"Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56(7):481\u201390.","journal-title":"J Clin Pathol"},{"issue":"3","key":"1599_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00467-010-1720-x","volume":"26","author":"M Edelbauer","year":"2011","unstructured":"Edelbauer M, et al. Markers of childhood lupus nephritis indicating disease activity. Pediatr Nephrol. 2011;26(3):401\u201310.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"1599_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10238-018-0491-8","volume":"18","author":"E Lukawska","year":"2018","unstructured":"Lukawska E, Polcyn-Adamczak M, Niemir ZI. The role of the alternative pathway of complement activation in glomerular diseases. Clin Exp Med. 2018;18(3):297\u2013318.","journal-title":"Clin Exp Med"},{"issue":"9","key":"1599_CR8","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.autrev.2018.03.013","volume":"17","author":"C Dumestre-Perard","year":"2018","unstructured":"Dumestre-Perard C, et al. Antibodies targeting circulating protective molecules in lupus nephritis: interest as serological biomarkers. Autoimmun Rev. 2018;17(9):890\u20139.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1599_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10067-017-3933-x","volume":"37","author":"J He","year":"2018","unstructured":"He J, Li Z. An era of biological treatment in systemic lupus erythematosus. Clin Rheumatol. 2018;37(1):1\u20133.","journal-title":"Clin Rheumatol"},{"key":"1599_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jaut.2016.06.014","volume":"74","author":"M Gatto","year":"2016","unstructured":"Gatto M, et al. Success and failure of biological treatment in systemic lupus erythematosus: a critical analysis. J Autoimmun. 2016;74:94\u2013105.","journal-title":"J Autoimmun"},{"issue":"6","key":"1599_CR11","first-page":"555","volume":"71","author":"N Wakamiya","year":"2019","unstructured":"Wakamiya N, et al. New complement therapeutics in complement-related diseases. Brain Nerve. 2019;71(6):555\u201364.","journal-title":"Brain Nerve"},{"issue":"3","key":"1599_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.clim.2013.02.014","volume":"148","author":"ML Barilla-Labarca","year":"2013","unstructured":"Barilla-Labarca ML, Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol. 2013;148(3):313\u201321.","journal-title":"Clin Immunol"},{"issue":"4","key":"1599_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","volume":"29","author":"E Benamu","year":"2016","unstructured":"Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016;29(4):319\u201329.","journal-title":"Curr Opin Infect Dis"},{"issue":"11","key":"1599_CR14","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1096\/fj.14-258046","volume":"28","author":"Q Qiao","year":"2014","unstructured":"Qiao Q, et al. A novel CRIg-targeted complement inhibitor protects cells from complement damage. FASEB J. 2014;28(11):4986\u201399.","journal-title":"FASEB J"},{"issue":"9","key":"1599_CR15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nrrheum.2017.125","volume":"13","author":"LA Trouw","year":"2017","unstructured":"Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13(9):538\u201347.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1599_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.molimm.2015.03.011","volume":"67","author":"RB Pouw","year":"2015","unstructured":"Pouw RB, et al. Of mice and men: the factor H protein family and complement regulation. Mol Immunol. 2015;67(1):12\u201320.","journal-title":"Mol Immunol"},{"issue":"Suppl","key":"1599_CR17","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.3346\/jkms.2009.24.S1.S7","volume":"24","author":"KE Sada","year":"2009","unstructured":"Sada KE, Makino H. Usefulness of ISN\/RPS classification of lupus nephritis. J Korean Med Sci. 2009;24(Suppl):S7\u201310.","journal-title":"J Korean Med Sci"},{"issue":"4","key":"1599_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00281-013-0413-5","volume":"36","author":"HJ Anders","year":"2014","unstructured":"Anders HJ, Fogo AB. Immunopathology of lupus nephritis. Semin Immunopathol. 2014;36(4):443\u201359.","journal-title":"Semin Immunopathol"},{"issue":"3","key":"1599_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/01.mnh.0000444816.57378.21","volume":"23","author":"G Lorenz","year":"2014","unstructured":"Lorenz G, Desai J, Anders HJ. Lupus nephritis: update on mechanisms of systemic autoimmunity and kidney immunopathology. Curr Opin Nephrol Hypertens. 2014;23(3):211\u20137.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"13","key":"1599_CR20","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1177\/0961203311415561","volume":"20","author":"N Sato","year":"2011","unstructured":"Sato N, et al. Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus. 2011;20(13):1378\u201386.","journal-title":"Lupus"},{"issue":"16","key":"1599_CR21","doi-asserted-by":"publisher","first-page":"8563","DOI":"10.1073\/pnas.93.16.8563","volume":"93","author":"Y Wang","year":"1996","unstructured":"Wang Y, et al. Amelioration of lupus-like autoimmune disease in NZB\/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A. 1996;93(16):8563\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1599_CR22","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00296-017-3686-5","volume":"37","author":"S Sciascia","year":"2017","unstructured":"Sciascia S, et al. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int. 2017;37(8):1249\u201355.","journal-title":"Rheumatol Int"},{"issue":"4","key":"1599_CR23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1053\/j.ajkd.2013.11.023","volume":"63","author":"BH Rovin","year":"2014","unstructured":"Rovin BH, Parikh SV. Lupus nephritis: the evolving role of novel therapeutics. Am J Kidney Dis. 2014;63(4):677\u201390.","journal-title":"Am J Kidney Dis"},{"key":"1599_CR24","doi-asserted-by":"crossref","unstructured":"Gackler A, et al. Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab. Nephrol Dial Transplant. 2018.","DOI":"10.1093\/ndt\/gfy225"},{"issue":"2","key":"1599_CR25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.clim.2015.05.006","volume":"160","author":"LA Lieberman","year":"2015","unstructured":"Lieberman LA, et al. Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease. Clin Immunol. 2015;160(2):286\u201391.","journal-title":"Clin Immunol"},{"issue":"16","key":"1599_CR26","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1016\/j.molimm.2008.07.011","volume":"45","author":"JQ He","year":"2008","unstructured":"He JQ, Wiesmann C, van Lookeren Campagne M. A role of macrophage complement receptor CRIg in immune clearance and inflammation. Mol Immunol. 2008;45(16):4041\u20137.","journal-title":"Mol Immunol"},{"issue":"4","key":"1599_CR27","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/art.30222","volume":"63","author":"H Sekine","year":"2011","unstructured":"Sekine H, et al. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL\/lpr mice. Arthritis Rheum. 2011;63(4):1076\u201385.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1599_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","volume":"30","author":"R Coppo","year":"2015","unstructured":"Coppo R, et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol. 2015;30(1):167\u201372.","journal-title":"Pediatr Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1599-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1599-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1599-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T20:58:54Z","timestamp":1605819534000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1599-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1599"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1599-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.12301\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.12301\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.12301\/v2","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"23 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review board of Children\u2019s Hospital of Fudan University ([2016]172).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed and approved the current manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"424"}}